Relapsed Adult AML Clinical Trial
Official title:
Phase-I/II Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
This is an open-label Phase I dose-escalation study of oral venetoclax in combination with increasing cytarabine doses plus mitoxantrone to define the safety profile and MTD of cytarabine in subjects with a histologically or cytologically confirmed acute myeloid leukemia who are refractory or suffered a relapse. This study will be conducted at multiple centers in Germany.
- To determine safety, tolerability, maximum tolerated dose, and recommended phase II dose of venetoclax in combination with increasing cytarabine doses plus fixed dose mitoxantrone in subjects with a relapsed or refractory AML considered fit for intensive salvage therapy. - To assess the preliminary efficacy of venetoclax in combination with increasing cytarabine doses plus fixed dose mitoxantrone in subjects with a relapsed or refractory AML considered fit for intensive salvage therapy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06141304 -
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
|
Phase 2 | |
Active, not recruiting |
NCT05029141 -
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT03848754 -
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Not yet recruiting |
NCT06007911 -
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT04722952 -
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML
|
Phase 3 | |
Withdrawn |
NCT03932318 -
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06307054 -
CLL-1 CAR-NK Cells for Relapsed/Refractory AML
|
Phase 1 | |
Recruiting |
NCT04310592 -
Natural Killer Cell (CYNK-001) Infusions in Adults With AML
|
Phase 1 | |
Recruiting |
NCT05237258 -
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
|
N/A | |
Active, not recruiting |
NCT04139434 -
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
|
Phase 1 | |
Completed |
NCT05193448 -
A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
|
||
Recruiting |
NCT03867682 -
Venetoclax and Lintuzumab-Ac225 in AML Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06022003 -
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT03091933 -
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05305859 -
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
|
Phase 2 | |
Approved for marketing |
NCT03245424 -
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
|